Renfeng Shan

473 total citations
27 papers, 297 citations indexed

About

Renfeng Shan is a scholar working on Cancer Research, Molecular Biology and Hepatology. According to data from OpenAlex, Renfeng Shan has authored 27 papers receiving a total of 297 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Cancer Research, 10 papers in Molecular Biology and 10 papers in Hepatology. Recurrent topics in Renfeng Shan's work include Hepatocellular Carcinoma Treatment and Prognosis (10 papers), MicroRNA in disease regulation (7 papers) and Circular RNAs in diseases (6 papers). Renfeng Shan is often cited by papers focused on Hepatocellular Carcinoma Treatment and Prognosis (10 papers), MicroRNA in disease regulation (7 papers) and Circular RNAs in diseases (6 papers). Renfeng Shan collaborates with scholars based in China and Canada. Renfeng Shan's co-authors include Jianfeng Li, Hua Qiu, Zhigao Hu, Jin Xie, Mengxi Xiu, Wei Deng, Jinfeng Tan, Tao Wang, Daya Luo and Lianghui Gao and has published in prestigious journals such as SHILAP Revista de lepidopterología, International Journal of Cancer and Journal of Cellular Physiology.

In The Last Decade

Renfeng Shan

25 papers receiving 295 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Renfeng Shan China 12 122 116 90 76 68 27 297
Nicolai Aagaard Schultz Denmark 9 121 1.0× 149 1.3× 79 0.9× 147 1.9× 81 1.2× 21 322
Masaharu Kogure Japan 11 297 2.4× 57 0.5× 34 0.4× 119 1.6× 100 1.5× 34 483
G. Maddalo Italy 9 66 0.5× 93 0.8× 61 0.7× 74 1.0× 139 2.0× 18 305
Ting‐Jung Wu Taiwan 11 82 0.7× 64 0.6× 165 1.8× 94 1.2× 113 1.7× 21 359
Quan Xu China 11 56 0.5× 38 0.3× 69 0.8× 68 0.9× 111 1.6× 28 258
Jean Philippe Metges France 8 110 0.9× 76 0.7× 23 0.3× 224 2.9× 85 1.3× 23 343
Helen Bolanaki Greece 8 138 1.1× 120 1.0× 15 0.2× 114 1.5× 78 1.1× 20 301
Burcin Özdirik Germany 12 56 0.5× 41 0.4× 105 1.2× 112 1.5× 69 1.0× 24 319
Linfeng Xu China 10 73 0.6× 64 0.6× 128 1.4× 40 0.5× 52 0.8× 24 251

Countries citing papers authored by Renfeng Shan

Since Specialization
Citations

This map shows the geographic impact of Renfeng Shan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Renfeng Shan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Renfeng Shan more than expected).

Fields of papers citing papers by Renfeng Shan

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Renfeng Shan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Renfeng Shan. The network helps show where Renfeng Shan may publish in the future.

Co-authorship network of co-authors of Renfeng Shan

This figure shows the co-authorship network connecting the top 25 collaborators of Renfeng Shan. A scholar is included among the top collaborators of Renfeng Shan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Renfeng Shan. Renfeng Shan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Chen, Wanqing, et al.. (2024). Prognostic Value of Alpha-Fetoprotein in Unresectable Hepatocellular Carcinoma Treated with Hepatic Artery Infusion Chemotherapy Combined with Lenvatinib and Camrelizumab. Journal of Hepatocellular Carcinoma. Volume 11. 1251–1263. 4 indexed citations
2.
3.
Tu, Shu‐Ju, et al.. (2024). Development and validation of nomograms to evaluate the survival outcome of HCC patients undergoing selective postoperative adjuvant TACE. La radiologia medica. 129(4). 653–664. 4 indexed citations
4.
5.
6.
Tong, Weilai, et al.. (2024). AURKB targets DHX9 to promote hepatocellular carcinoma progression via PI3K/AKT/mTOR pathway. Molecular Carcinogenesis. 63(9). 1814–1826. 10 indexed citations
7.
Shan, Renfeng, et al.. (2023). Development and Validation of a Nomogram for Predicting Postoperative Early Relapse and Survival in Hepatocellular Carcinoma. Journal of the National Comprehensive Cancer Network. 22(1D). 1–7.e42. 13 indexed citations
8.
9.
10.
Wang, Tao, et al.. (2022). Hepatectomy After Conversion Therapy for Initially Unresectable HCC: What is the Difference?. SHILAP Revista de lepidopterología. Volume 9. 1353–1368. 23 indexed citations
11.
Wang, Tao, et al.. (2022). Rare benign liver tumors that require differentiation from hepatocellular carcinoma: focus on diagnosis and treatment. Journal of Cancer Research and Clinical Oncology. 149(7). 2843–2854. 4 indexed citations
12.
13.
Xiu, Mengxi, et al.. (2021). Targeting Notch4 in Cancer: Molecular Mechanisms and Therapeutic Perspectives. Cancer Management and Research. Volume 13. 7033–7045. 20 indexed citations
14.
Liu, Wei, et al.. (2021). The Roles of circMTO1 in Cancer. Frontiers in Cell and Developmental Biology. 9. 656258–656258. 12 indexed citations
15.
Xiu, Mengxi, et al.. (2020). The oncogenic role of HBXIP. Biomedicine & Pharmacotherapy. 133. 111045–111045. 13 indexed citations
16.
Qiu, Hua, et al.. (2020). Long-term oncological outcomes in robotic versus laparoscopic approach for rectal cancer: A systematic review and meta-analysis. International Journal of Surgery. 80. 225–230. 27 indexed citations
17.
Shi, Jun, et al.. (2019). Risk factors for 30-day unplanned reoperation after pancreatoduodenectomy: A single-center experience. Journal of Cancer Research and Therapeutics. 15(7). 1530–1530. 8 indexed citations
18.
Shan, Renfeng, et al.. (2019). Effectiveness and safety of robotic versus traditional laparoscopic gastrectomy for gastric cancer: An updated systematic review and meta-analysis. Journal of Cancer Research and Therapeutics. 15(7). 1450–1450. 15 indexed citations
19.
Wang, Hongmei, et al.. (2017). Liver transplantation for decompensated liver cirrhosis caused by progressive familial intrahepatic cholestasis type 3. Medicine. 96(50). e9158–e9158. 4 indexed citations
20.
Lin, Huashan, et al.. (2015). Adjuvant chemotherapy after liver transplantation for hepatocellular carcinoma: a systematic review and a meta-analysis. Hepatobiliary & pancreatic diseases international. 14(3). 236–245. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Nicolai Aagaard Schultz Breakdown of academic impact, for papers by Masaharu Kogure Breakdown of academic impact, for papers by G. Maddalo Breakdown of academic impact, for papers by Ting‐Jung Wu Breakdown of academic impact, for papers by Quan Xu Breakdown of academic impact, for papers by Jean Philippe Metges Breakdown of academic impact, for papers by Helen Bolanaki Breakdown of academic impact, for papers by Burcin Özdirik Breakdown of academic impact, for papers by Linfeng Xu
Rankless by CCL
2026